Pilot clinical studies on patients with different stages of prostate
cancer, breast cancer, and ovarian cancer using a new cancer marker MEC showed
>90% Sensitivity with 95% Specificity of the test for early stages of
cancer. Monitoring the dynamics of the cancer marker CA-62 for the patients
with advanced stages of cancer during a course of chemotherapy have
demonstrated a very good correlation between expression of CA-62 marker and a
clinical status of the patient according to the criterion RECIST. Within the
framework of this project an industrial set of reagents will be developed for
cancer treatment monitoring and for early detection of cancer based on the MEC
biomarker. The test system is expected to be registered in RF and abroad, as
well as organization of its manufacturing
Pipeline
JVS Diagnostics llc